Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Key Findings

  • Comprehensive ctDNA testing can effectively guide therapy selection
  • Response rates to therapy selected based on Guardant360 results were consistent with those in tissue-based targeted therapy studies

"Among patients with insufficient tumor tissue for sequencing, ctDNA testing can be a feasible option to guide molecularly matched therapy."

Seung Tae Kim, MD

Study Overview

In this prospective analysis of 193 advanced cancer patients profiled with the Guardant360 assay, the objective response rate for patients in the NSCLC arm who were matched to targeted therapy was 87%. The disease control rate was 100%.

Points for your practice

  • This prospective study demonstrated the clinical utility of using ctDNA to guide treatment selection in advanced cancer patients
  • A quarter of the patients in the NSCLC cohort were matched to targeted therapy
  • Response was documented for points mutations, fusions, and deletion events
  • Objective response was achieved even at low variant allele fraction

You may also
be interested in...

Clinical lung cancer

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

View Publication View Publication

Specification Sheet

Guardant360® provides guideline-recommended genomic results in 7 days from a routine blood draw, eliminating the need to solely rely on tissue testing.

View Publication Download material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.